These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

508 related articles for article (PubMed ID: 30151994)

  • 21. Clinical impact of vonoprazan-based dual therapy with amoxicillin for H. pylori infection in a treatment-naïve cohort of junior high school students in Japan.
    Gotoda T; Kusano C; Suzuki S; Horii T; Ichijima R; Ikehara H
    J Gastroenterol; 2020 Oct; 55(10):969-976. PubMed ID: 32666199
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Triple therapy with ecabet sodium, amoxicillin and lansoprazole for 2 weeks as the rescue regimen for H. pylori infection.
    Furuta T; Kato M; Sugimoto M; Sasaki M; Kamoshida T; Furukawa K; Inaba T; Tomita T; Shirai T; Ishii N; Nomura H; Konda Y; Asaka M;
    Intern Med; 2011; 50(5):369-74. PubMed ID: 21372444
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Vonoprazan-containing Helicobacter pylori triple therapies contribution to global antimicrobial resistance.
    Graham DY; Lu H; Shiotani A
    J Gastroenterol Hepatol; 2021 May; 36(5):1159-1163. PubMed ID: 32918832
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Randomized clinical trial comparing ten day concomitant and sequential therapies for Helicobacter pylori eradication in a high clarithromycin resistance area.
    Georgopoulos SD; Xirouchakis E; Martinez-Gonzales B; Zampeli E; Grivas E; Spiliadi C; Sotiropoulou M; Petraki K; Zografos K; Laoudi F; Sgouras D; Mentis A; Kasapidis P; Michopoulos S
    Eur J Intern Med; 2016 Jul; 32():84-90. PubMed ID: 27134145
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Concomitant and hybrid therapy for Helicobacter pylori infection: A randomized clinical trial.
    Heo J; Jeon SW; Jung JT; Kwon JG; Lee DW; Kim HS; Yang CH; Park JB; Park KS; Cho KB; Lee SH; Jang BI;
    J Gastroenterol Hepatol; 2015 Sep; 30(9):1361-6. PubMed ID: 25867608
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Changes in the first line Helicobacter pylori eradication rates using the triple therapy-a multicenter study in the Tokyo metropolitan area (Tokyo Helicobacter pylori study group).
    Kawai T; Takahashi S; Suzuki H; Sasaki H; Nagahara A; Asaoka D; Matsuhisa T; Masaoaka T; Nishizawa T; Suzuki M; Ito M; Kurihara N; Omata F; Mizuno S; Torii A; Kawakami K; Ohkusa T; Tokunaga K; Mine T; Sakaki N
    J Gastroenterol Hepatol; 2014 Dec; 29 Suppl 4():29-32. PubMed ID: 25521730
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of moxifloxacin-based sequential and hybrid therapy for first-line Helicobacter pylori eradication.
    Hwang JJ; Lee DH; Yoon H; Shin CM; Park YS; Kim N
    World J Gastroenterol; 2015 Sep; 21(35):10234-41. PubMed ID: 26401089
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of triple therapy with esomeprazole, amoxicillin, and sitafloxacin as a third-line Helicobacter pylori eradication regimen.
    Hirata Y; Serizawa T; Shichijo S; Suzuki N; Sakitani K; Hayakawa Y; Yamada A; Koike K
    Int J Infect Dis; 2016 Oct; 51():66-69. PubMed ID: 27590563
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical trial: seven-day vonoprazan- versus 14-day proton pump inhibitor-based triple therapy for first-line Helicobacter pylori eradication.
    Ang D; Koo SH; Chan YH; Tan TY; Soon GH; Tan CK; Lin KW; Krishnasamy-Balasubramanian JK; Wong YJ; Kumar R; R R; Tan Y; Ong PJ; Tan YJ; Li JW; Kwek AB; Ang TL
    Aliment Pharmacol Ther; 2022 Aug; 56(3):436-449. PubMed ID: 35665947
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vonoprazan, a Novel Potassium-Competitive Acid Blocker, Should Be Used for the Helicobacter pylori Eradication Therapy as First Choice: A Large Sample Study of Vonoprazan in Real World Compared with Our Randomized Control Trial Using Second-Generation Proton Pump Inhibitors for Helicobacter pylori Eradication Therapy.
    Ozaki H; Harada S; Takeuchi T; Kawaguchi S; Takahashi Y; Kojima Y; Ota K; Hongo Y; Ashida K; Sakaguchi M; Tokioka S; Sakamoto H; Furuta T; Tominaga K; Higuchi K
    Digestion; 2018; 97(3):212-218. PubMed ID: 29393194
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Vonoprazan-based triple therapy is effective for Helicobacter pylori eradication irrespective of clarithromycin susceptibility.
    Okubo H; Akiyama J; Kobayakawa M; Kawazoe M; Mishima S; Takasaki Y; Nagata N; Shimada T; Yokoi C; Komori S; Kimura K; Hisada Y; Iwata E; Watanabe K; Yanagisawa N; Shiroma S; Shimomura A; Okahara K; Cho H; Uemura N
    J Gastroenterol; 2020 Nov; 55(11):1054-1061. PubMed ID: 32930864
    [TBL] [Abstract][Full Text] [Related]  

  • 32. 14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial.
    Greenberg ER; Anderson GL; Morgan DR; Torres J; Chey WD; Bravo LE; Dominguez RL; Ferreccio C; Herrero R; Lazcano-Ponce EC; Meza-Montenegro MM; Peña R; Peña EM; Salazar-Martínez E; Correa P; Martínez ME; Valdivieso M; Goodman GE; Crowley JJ; Baker LH
    Lancet; 2011 Aug; 378(9790):507-14. PubMed ID: 21777974
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Vonoprazan-based triple therapy is non-inferior to susceptibility-guided proton pump inhibitor-based triple therapy for Helicobacter pylori eradication.
    Tanabe H; Yoshino K; Ando K; Nomura Y; Ohta K; Satoh K; Ichiishi E; Ishizuka A; Otake T; Kohgo Y; Fujiya M; Okumura T
    Ann Clin Microbiol Antimicrob; 2018 Jun; 17(1):29. PubMed ID: 29950163
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Triple-Drug Blister-Packaged Drug with Vonoprazan Improves First-Line Eradication of Helicobacter pylori in Elderly Patients: A Retrospective Propensity Score-Matched Cohort Study.
    Nishida T; Tsujii Y; Okamoto A; Tomita R; Higaki Y; Osugi N; Sugimoto A; Takahashi K; Mukai K; Nakamatsu D; Matsubara T; Hayashi S; Yamamoto M; Nakajima S; Fukui K; Inada M
    Digestion; 2020; 101(5):608-614. PubMed ID: 31288235
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Optimum duration of regimens for Helicobacter pylori eradication.
    Yuan Y; Ford AC; Khan KJ; Gisbert JP; Forman D; Leontiadis GI; Tse F; Calvet X; Fallone C; Fischbach L; Oderda G; Bazzoli F; Moayyedi P
    Cochrane Database Syst Rev; 2013 Dec; (12):CD008337. PubMed ID: 24338763
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Superiority of Vonoprazan-based First-line Triple Therapy with Clarithromycin: A Prospective Multi-center Cohort Study on Helicobacter pylori Eradication.
    Sue S; Kuwashima H; Iwata Y; Oka H; Arima I; Fukuchi T; Sanga K; Inokuchi Y; Ishii Y; Kanno M; Terada M; Amano H; Naito M; Iwase S; Okazaki H; Komatsu K; Kokawa A; Kawana I; Morimoto M; Saito T; Kunishi Y; Ikeda A; Takahashi D; Miwa H; Sasaki T; Tamura T; Kondo M; Shibata W; Maeda S
    Intern Med; 2017; 56(11):1277-1285. PubMed ID: 28566587
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Seven-day vonoprazan and low-dose amoxicillin dual therapy as first-line
    Suzuki S; Gotoda T; Kusano C; Ikehara H; Ichijima R; Ohyauchi M; Ito H; Kawamura M; Ogata Y; Ohtaka M; Nakahara M; Kawabe K
    Gut; 2020 Jun; 69(6):1019-1026. PubMed ID: 31915235
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A randomized trial of lansoprazole, amoxycillin, and clarithromycin versus lansoprazole, bismuth, metronidazole and tetracycline in the retreatment of patients failing initial Helicobacter pylori therapy.
    Magaret N; Burm M; Faigel D; Kelly C; Peterson W; Fennerty MB
    Dig Dis; 2001; 19(2):174-8. PubMed ID: 11549829
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The multicenter real-world report of the efficacies of 14-day esomeprazole-based and rabeprazole-based high-dose dual therapy in first-line Helicobacter pylori eradication in Taiwan.
    Tai WC; Wu IT; Wang HM; Huang PY; Yao CC; Wu CK; Yang SC; Liang CM; Hsu PI; Chuah SK
    J Microbiol Immunol Infect; 2024 Aug; 57(4):601-608. PubMed ID: 38461114
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Systematic review with meta-analysis: Vonoprazan, a potent acid blocker, is superior to proton-pump inhibitors for eradication of clarithromycin-resistant strains of Helicobacter pylori.
    Li M; Oshima T; Horikawa T; Tozawa K; Tomita T; Fukui H; Watari J; Miwa H
    Helicobacter; 2018 Aug; 23(4):e12495. PubMed ID: 29873436
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.